Anti- Human IFN gamma mAb (CAP) (RMK0037)

Interferon-gamma (IFN-γ) is an important immunomodulatory cytokine, affecting both the innate and adaptive immune systems.It was discovered in 1965 as a soluble anti-viral factor and has since been shown to promote host defense against a wide variety of pathogens. IFN-γ signaling plays a key role in host defense by promoting macrophage activation,upregulating the expression of antigen processing and presentation molecules, driving the development and activation of Th1 cells, enhancing natural killer cell activity, regulating B cell functions, and inducing the production of chemokines that promote effector cell trafficking to sites of inflammation.Receptor subunit for interferon gamma/INFG that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation.Associates with transmembrane accessory factor IFNGR2 to form a functional receptor.Upon ligand binding, the intracellular domain of IFNGR1 opens out to allow association of downstream signaling components JAK1 and JAK2. In turn, activated JAK1 phosphorylates IFNGR1 to form a docking site for STAT1. Subsequent phosphorylation of STAT1 leads to dimerization, translocation to the nucleus, and stimulation of target gene transcription. STAT3 can also be activated in a similar manner although activation seems weaker. IFNGR1 intracellular domain phosphorylation also provides a docking site for SOCS1 that regulates the JAK-STAT pathway by competing with STAT1 binding to IFNGR1.